vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Esquire Financial Holdings, Inc. (ESQ). Click either name above to swap in a different company.

Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $40.5M, roughly 1.5× Esquire Financial Holdings, Inc.). Esquire Financial Holdings, Inc. runs the higher net margin — 30.2% vs -70.9%, a 101.1% gap on every dollar of revenue. Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 15.0%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Esquire Financial Holdings, Inc. is a U.S.-headquartered bank holding company that provides comprehensive commercial and consumer banking products and services. Its core offerings include deposit accounts, business loans, mortgage services, and wealth management solutions, primarily serving small to medium enterprises, legal industry professionals, and local retail clients.

CTKB vs ESQ — Head-to-Head

Bigger by revenue
CTKB
CTKB
1.5× larger
CTKB
$62.1M
$40.5M
ESQ
Higher net margin
ESQ
ESQ
101.1% more per $
ESQ
30.2%
-70.9%
CTKB
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
15.0%
ESQ

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CTKB
CTKB
ESQ
ESQ
Revenue
$62.1M
$40.5M
Net Profit
$-44.1M
$12.2M
Gross Margin
52.9%
Operating Margin
-9.0%
Net Margin
-70.9%
30.2%
Revenue YoY
8.1%
Net Profit YoY
-557.1%
7.0%
EPS (diluted)
$1.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
ESQ
ESQ
Q1 26
$40.5M
Q4 25
$62.1M
$39.4M
Q3 25
$52.3M
$37.6M
Q2 25
$45.6M
$35.8M
Q1 25
$41.5M
$33.8M
Q4 24
$57.5M
$33.1M
Q3 24
$51.5M
$31.9M
Q2 24
$46.6M
$30.6M
Net Profit
CTKB
CTKB
ESQ
ESQ
Q1 26
$12.2M
Q4 25
$-44.1M
$13.5M
Q3 25
$-5.5M
$14.1M
Q2 25
$-5.6M
$11.9M
Q1 25
$-11.4M
$11.4M
Q4 24
$9.6M
$11.8M
Q3 24
$941.0K
$11.4M
Q2 24
$-10.4M
$10.5M
Gross Margin
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
52.9%
Q3 25
52.7%
Q2 25
52.3%
Q1 25
48.6%
Q4 24
58.5%
Q3 24
56.3%
Q2 24
54.6%
Operating Margin
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
-9.0%
44.3%
Q3 25
-17.6%
46.5%
Q2 25
-23.3%
42.5%
Q1 25
-36.1%
45.9%
Q4 24
5.2%
47.4%
Q3 24
-8.2%
48.8%
Q2 24
-18.3%
46.9%
Net Margin
CTKB
CTKB
ESQ
ESQ
Q1 26
30.2%
Q4 25
-70.9%
34.2%
Q3 25
-10.5%
37.4%
Q2 25
-12.2%
33.2%
Q1 25
-27.5%
33.8%
Q4 24
16.8%
35.6%
Q3 24
1.8%
35.6%
Q2 24
-22.4%
34.3%
EPS (diluted)
CTKB
CTKB
ESQ
ESQ
Q1 26
$1.40
Q4 25
$1.54
Q3 25
$1.62
Q2 25
$1.38
Q1 25
$1.33
Q4 24
$1.35
Q3 24
$1.34
Q2 24
$1.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
ESQ
ESQ
Cash + ST InvestmentsLiquidity on hand
$90.9M
$222.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$301.3M
Total Assets
$461.5M
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
ESQ
ESQ
Q1 26
$222.2M
Q4 25
$90.9M
$235.9M
Q3 25
$93.3M
$240.8M
Q2 25
$75.5M
$163.0M
Q1 25
$95.3M
$173.0M
Q4 24
$98.7M
$126.3M
Q3 24
$162.3M
$147.7M
Q2 24
$177.9M
$152.7M
Stockholders' Equity
CTKB
CTKB
ESQ
ESQ
Q1 26
$301.3M
Q4 25
$341.7M
$289.6M
Q3 25
$378.6M
$279.2M
Q2 25
$377.6M
$263.6M
Q1 25
$379.6M
$250.7M
Q4 24
$395.7M
$237.1M
Q3 24
$385.5M
$232.6M
Q2 24
$389.1M
$217.4M
Total Assets
CTKB
CTKB
ESQ
ESQ
Q1 26
$2.4B
Q4 25
$461.5M
$2.4B
Q3 25
$494.9M
$2.2B
Q2 25
$493.3M
$2.1B
Q1 25
$482.6M
$2.0B
Q4 24
$499.5M
$1.9B
Q3 24
$491.2M
$1.8B
Q2 24
$483.7M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
ESQ
ESQ
Operating Cash FlowLast quarter
$-771.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-2.9%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
$-771.0K
$59.8M
Q3 25
$-3.9M
$16.8M
Q2 25
$108.0K
$10.5M
Q1 25
$-125.0K
$15.8M
Q4 24
$2.0M
$42.2M
Q3 24
$13.2M
$10.5M
Q2 24
$6.2M
$7.2M
Free Cash Flow
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
$-1.8M
$56.7M
Q3 25
$-4.6M
$16.2M
Q2 25
$-1.5M
$9.3M
Q1 25
$-974.0K
$14.7M
Q4 24
$1.1M
$41.5M
Q3 24
$12.2M
$10.5M
Q2 24
$5.2M
$6.9M
FCF Margin
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
-2.9%
143.9%
Q3 25
-8.7%
43.2%
Q2 25
-3.2%
26.0%
Q1 25
-2.3%
43.4%
Q4 24
1.9%
125.5%
Q3 24
23.7%
32.8%
Q2 24
11.0%
22.5%
Capex Intensity
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
1.6%
8.0%
Q3 25
1.3%
1.3%
Q2 25
3.5%
3.2%
Q1 25
2.0%
3.4%
Q4 24
1.6%
2.2%
Q3 24
2.0%
0.2%
Q2 24
2.3%
1.1%
Cash Conversion
CTKB
CTKB
ESQ
ESQ
Q1 26
Q4 25
4.44×
Q3 25
1.19×
Q2 25
0.88×
Q1 25
1.39×
Q4 24
0.21×
3.59×
Q3 24
14.05×
0.93×
Q2 24
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

ESQ
ESQ

Net Interest Income$34.0M84%
Noninterest Income$6.5M16%

Related Comparisons